Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it has completed enrollment in its Phase 2
clinical trial with revusiran (re-VOO-si-ran), the recommended
International Nonproprietary Name (INN) for ALN-TTRsc.
for Alnylam Completes Phase 2 Enrollment and Initiates Open-Label Extension (OLE) Study with Revusiran (ALN-TTRsc), an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR Cardiac Amyloidosis investment picks